Jump to navigation Jump to search
CAS Number
PubChem CID
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Molar mass238.285 g/mol

WikiDoc Resources for Semaxanib


Most recent articles on Semaxanib

Most cited articles on Semaxanib

Review articles on Semaxanib

Articles on Semaxanib in N Eng J Med, Lancet, BMJ


Powerpoint slides on Semaxanib

Images of Semaxanib

Photos of Semaxanib

Podcasts & MP3s on Semaxanib

Videos on Semaxanib

Evidence Based Medicine

Cochrane Collaboration on Semaxanib

Bandolier on Semaxanib

TRIP on Semaxanib

Clinical Trials

Ongoing Trials on Semaxanib at Clinical

Trial results on Semaxanib

Clinical Trials on Semaxanib at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Semaxanib

NICE Guidance on Semaxanib


FDA on Semaxanib

CDC on Semaxanib


Books on Semaxanib


Semaxanib in the news

Be alerted to news on Semaxanib

News trends on Semaxanib


Blogs on Semaxanib


Definitions of Semaxanib

Patient Resources / Community

Patient resources on Semaxanib

Discussion groups on Semaxanib

Patient Handouts on Semaxanib

Directions to Hospitals Treating Semaxanib

Risk calculators and risk factors for Semaxanib

Healthcare Provider Resources

Symptoms of Semaxanib

Causes & Risk Factors for Semaxanib

Diagnostic studies for Semaxanib

Treatment of Semaxanib

Continuing Medical Education (CME)

CME Programs on Semaxanib


Semaxanib en Espanol

Semaxanib en Francais


Semaxanib in the Marketplace

Patents on Semaxanib

Experimental / Informatics

List of terms related to Semaxanib


Semaxanib (proposed INN,[1] also semaxinib or SU5416) is a drug intended for use in the treatment of cancer. It is still at an experimental stage and as such has not yet received a licence for use on human patients (except in the setting of a clinical trial). Semaxanib is a potent and selective synthetic inhibitor of the Flk-1/KDR vascular endothelial growth factor (VEGF) receptor tyrosine kinase. It targets the VEGF pathway, and both in vivo and in vitro studies have demonstrated antiangiogenic potential.

On February 2002, Pharmacia, the developer of semaxanib, prematurely ended Phase III clinical trials it was conducting on the drug's effectiveness in the treatment of advanced colorectal cancer due to discouraging results.[2] Other studies, at earlier phases, have since been conducted.[3] [4] However, due to the prospect of next-generation tyrosine kinase inhibitors and the ineffaciousness of semaxanib in clinic trials, further development of the drug has been discontinued.[5]


  1. World Health Organization (2001). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 85". WHO Drug Information. 15 (2). Template:PDFlink
  2. "Pharmacia Announces Closing of SU5416 (semaxanib) Clinical Trials" (Press release). February 8, 2002. Retrieved 2007-03-20.
  3. O'Donnell A, Padhani A, Hayes C, Kakkar A, Leach M, Trigo J, Scurr M, Raynaud F, Phillips S, Aherne W, Hardcastle A, Workman P, Hannah A, Judson I (2005). "A Phase I study of the angiogenesis inhibitor SU5416 (semaxanib) in solid tumours, incorporating dynamic contrast MR pharmacodynamic end points". Br J Cancer. 93 (8): 876&ndash, 83. PMID 16222321.
  4. Lockhart A, Cropp G, Berlin J, Donnelly E, Schumaker R, Schaaf L, Hande K, Fleischer A, Hannah A, Rothenberg M (2006). "Phase I/pilot study of SU5416 (semaxinib) in combination with irinotecan/bolus 5-FU/LV (IFL) in patients with metastatic colorectal cancer". Am J Clin Oncol. 29 (2): 109&ndash, 15. PMID 16601426.
  5. Hoff, PM; et al. (2006). "A Phase I Study of Escalating Doses of the Tyrosine Kinase Inhibitor Semaxanib (SU5416) in Combination with Irinotecan in Patients with Advanced Colorectal Carcinoma". Japanese Journal of Clinical Oncology. 36 (2): 100–103.

Template:WH Template:WikiDoc Sources